Royalty Pharma (RPRX) to Release Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will be posting its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect Royalty Pharma to post earnings of $0.95 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter in the prior year, the company posted $0.85 earnings per share. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Stock Down 0.4 %

Shares of NASDAQ RPRX opened at $27.15 on Wednesday. The business has a 50-day moving average of $28.02 and a two-hundred day moving average of $27.58. The company has a market capitalization of $16.22 billion, a price-to-earnings ratio of 20.26, a price-to-earnings-growth ratio of 3.97 and a beta of 0.46. Royalty Pharma has a 1 year low of $25.20 and a 1 year high of $31.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s payout ratio is 62.69%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on RPRX shares. The Goldman Sachs Group boosted their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Citigroup reduced their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. StockNews.com lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Morgan Stanley upped their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.